Talazoparib

他拉唑帕利

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTalazoparib
Drug Alias NameTalazoparib tosylate他佐帕利他拉唑帕尼他拉唑帕利甲苯磺酸他拉唑帕利 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsSolid tumours +[39] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantBreast Neoplasms
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date2018/10/16
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteUniversity Medical Center GroningenBiomarin Pharmaceutical Inc +[13] 
Inactive CompaniesWashington University School Of MedicineStanford UniversityBrown University +[7] 
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[23] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsMyelodysplastic SyndromesNeoplasm Metastasis +[16] 

Other Information

ATC CodeL01XK04
Related LinksWikipediaDrugBankKEGG